Mechanistic investigations suggest that melittin suppresses breast cancer progression by inhibiting growth factor receptor activation (e.g., HER2) and inducing apoptosis through caspase activation and modulation of the Bax/Bcl-2 pathways [11,74]. The gene discussed is ERBB2; the disease is breast carcinoma.